Triad Life Sciences

Triad Life Sciences, Inc., an emerging regenerative medicine company, was founded in 2017 to address unmet clinical needs in complex surgical wounds, chronic or hard-to-heal wounds, and burns. Since then, our groundbreaking, proprietary, patent-pending, FDA-cleared technology platform has developed an array of innovative wound management solutions.

In 2022, Triad Life Sciences, Inc. was acquired by Convatec to support its strategy, securing access to a complementary and innovative technology platform that enhances advanced wound management and patient outcomes.

Founded to disrupt the extracellular matrix (ECM) market with a platform technology that introduces the first-ever placental-derived medical device, our company addresses the inherent challenges and related restrictions of human cells, tissues, and cellular and tissue-based products (HCT/Ps).

Our leadership team has a collective 100+ years of medical device experience at biologics companies and more than 30 years of combined experience specifically in ECM technologies.

Our leaders identified three key challenges with placental allografts manufactured from HCT/Ps: graft variability and inconsistency, minimal manipulation requirements, and the economics of care. The InnovaMatrix Platform offers a unique, unparalleled solution to these challenges^1-8 while also providing the reliability, reproducibility, and safety profile of a medical device^9,10.